The content on this site is intended for healthcare professionals only
Prof Matti Aapro speaks to ecancer at the BGICC 2020 conference in Cairo, Egypt about some of the issues surrounding breast cancer treatment.
He begins by discussing whether CDK4/6 inhibitors should be combined with endocrine therapy as a first-line treatment in patients who present with metastatic disease.
Prof Aapro also explores the use of trastuzumab in the adjuvant setting and questions whether it should be used for 12 months versus 6 months.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer
Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert round up July 28th to August 3rd, 2023
Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis
Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
Management of HER2 positive metastatic breast cancer treatment algorithm
